Jennifer Clarke



Dr. Jennifer Clarke is a neuro-oncologist, or brain cancer specialist, at UCSF Medical Center. In particular, she is interested in recurring tumors and in treating tumors with anti-angiogenic agents, which are substances designed to inhibit tumor growth by blocking development of new blood vessels. In her studies at the UCSF Brain Tumor Research Center, she investigates new imaging methods for diagnosing tumors and measuring their response to treatment. She is also interested in quality of life issues for brain tumor patients and their caregivers.

Clarke earned a medical degree at the UCSF School of Medicine, then completed a residency in neurology at UCSF and a fellowship in neuro-oncology at Memorial Sloan Kettering Cancer Center in New York. She is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-Oncology.

  • Education

    UCSF, 2002

  • Residencies

    UCSF Medical Center, Neurology, 2006

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Neuro-Oncology, 2008

  • Academic Title


Clinics I work with

Brain Tumor Center

400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143

My reviews


Overall Experience
166 Reviews
Dr Clarke has been an amazing care provider that I not only would recommend but look forward to her care for the rest of my life.
Explained things in a way that was easy to understand
165 Reviews
Did the doctor pay attention to your concerns
164 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
158 Reviews
Knew the important information about your medical history
165 Reviews
The provider showed respect for what you had to say
164 Reviews
The provider spent enough time with me
164 Reviews
Decorative Caduceus

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Ch...

To measure changes in tumor infiltrating T lymphocyte (TIL) density. It will be assessed using pooled Group A and Group B patients and compared to appropriate historical controls.


Decorative Caduceus

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenoty...

patients with stable disease will be considered responders if disease is stable for 27 weeks or more. The regimen will be considered worthy of further study if responses as defined above are observed in at least 3 of the 12 subjec...